Angel Reyes Blog : Angel Reyes : Texas Litigation Lawyer and Attorney : Dangerous Drugs : Wrongful Death : Business Litigation

Following a study published in the May 14, 2008 issue of The New England Journal of Medicine, Bayer Pharmaceuticals informed the FDA (Food & Drug Administration) of their plan to remove all remaining supplies of Trasylol (aprotinin injection) from hospital pharmacies and warehouses.  Due to the potential risks of this dangerous drug, which is used to prevent bleeding and blood clotting in patients during heart surgery, a special use agreement now limits Trasylol to treatment of patients who have no acceptable alternative therapy. Read the specifics of this special treatment protocol in the following FDA Alert: Continue Reading...

• Email This
• Print
• Comments
• Trackbacks
• Share Link

For almost two years, Trasylol, a drug used to prevent blood loss during surgery was under scrutiny by the FDA.  In fact, on February, 2006, the FDA issued a Public Health Advisory warning doctors who perform heart bypass surgery and their patients that Trasylol (generic name aprotinin) was linked in two scientific studies to severe side effects, including kidney problems, heart attacks and strokes in patients undergoing artery bypass graft surgery. Continue Reading...

• Email This
• Print
• Comments
• Trackbacks
• Share Link

On Thursday, October 25th, the Food and Drug Administration (FDA) stated that Trasylol, a drug used during heart bypass surgery to prevent severe bleeding, increases the risk of death as compared to other drugs. Continue Reading...

• Email This
• Print
• Comments (3)
• Trackbacks
• Share Link